[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354191-105":59,"doc-detail-354191-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","targeting-psmd14-enhances-immunotherapy-efficacy-by-promoting-pd-l1-degradation-and-reshaping-the-tumor-microenvironment-in-breast-cancer","Targeting PSMD14 enhances immunotherapy efficacy by promoting PD-L1 degradation and reshaping the tumor microenvironment in breast cancer","","Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors show encouraging breast cancer activity, yet durable responses remain difficult due to the immunosuppressive tumor microenvironment (TME). PSMD14, a deubiquitinating enzyme, is investigated for its role in immune evasion. PSMD14 expression is analyzed across databases and patient samples, validating its link to PD-L1 and defining how PSMD14-driven deubiquitination reshapes TME components and improves immunotherapy outcomes.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-psmd14-enhances-immunotherapy-efficacy-by-promoting-pd-l1-degradation-and-reshaping-the-tumor-microenvironment-in-breast-cancer/354191/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-psmd14-enhances-immunotherapy-efficacy-by-promoting-pd-l1-degradation-and-reshaping-the-tumor-microenvironment-in-breast-cancer/354191.png","ImageObject",300,407,{"name":92,"@type":93},"Cipher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",17,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What problem does the study address in breast cancer immunotherapy?","Question",{"text":113,"@type":114},"The study targets the challenge of achieving durable clinical responses to PD-1/PD-L1 inhibitors, which is hindered by an immunosuppressive tumor microenvironment (TME).","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does PSMD14 influence PD-L1 in breast cancer?",{"text":118,"@type":114},"PSMD14 stabilizes PD-L1 by interacting with its intracellular domain and removing K48-linked polyubiquitin chains, which inhibits proteasomal degradation.",{"name":120,"@type":111,"acceptedAnswer":121},"What is the impact of inhibiting PSMD14 on the TME and immunotherapy response?",{"text":122,"@type":114},"Inhibition of PSMD14 enhances antigen presentation and CD8+ T cell activation, reduces regulatory T cells and MDSCs, alters macrophage polarization, and collectively improves immunotherapy effectiveness.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},354191,1790194564,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},687208528416,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Wen et al. Journal of Experimental & Clinical Cancer Research (2026) 45:124 [https://doi.org/10.1186/s13046-026-03710-w](https://doi.org/10.1186/s13046-026-03710-w)  \nJournal of Experimental & Clinical Cancer Research  \nRESEARCH Open Access  \nTargeting PSMD14 enhances immunotherapy efficacy by promoting PD-L1 degradation and reshaping the tumor microenvironment in breast cancer  \nShichao Wen1†, Yuhan Liu1†, Qi Liu1, Liqian Su2, Yuhua Wang1, Yiqiu Ma1 and Jingxuan Wang1*  \nAbstract  \nBackground Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors have shown encouraging clinical efficacy in breast cancer, primarily by modulating the tumor microenvironment (TME) . However, achieving durable clinical responses remains a major challenge. Although the deubiquitinating enzyme 26S proteasome non-ATPase regulatory subunit 14 (PSMD14) is known to exert oncogenic functions in various cancers, its potential role in regulating tumor immune evasion remains unclear. This study investigates how PSMD14 regulates PD-L1 and reshapes the TME, with the goal of clarifying its impact on immune regulation in breast cancer.  \nMethods PSMD14 expression and its prognostic significance in breast cancer were analyzed using public databasesand clinical samples. The correlation between PSMD14 and PD-L1 was validated by immunohistochemistry (IHC), western blot, and flow cytometry. The mechanism by which PSMD14 stabilizes PD-L1 through deubiquitination and their interaction was investigated using cycloheximide chase assays, co-immunoprecipitation (Co-IP), and ubiquitination assays. The impact of PSMD14 on theTME and its influence on immunotherapy efficacy were evaluated using T cell cytotoxicity assays, syngeneic mouse models, and flow cytometry analyses.  \nResults PSMD14 was highly expressed in breast cancer and correlated with poor patient prognosis. Mechanistically, PSMD14 stabilized PD-L1 by interacting with its intracellular domain and removing its K48-linked polyubiquitin chains, thereby inhibiting proteasomal degradation. Inhibition of PSMD14 enhanced antigen presentation and CD8⁺ T cell activation, reduced the accumulation of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), and altered macrophage polarization. These changes collectively improved the response to immunotherapy in breast cancer.  \nConclusion This study identifies PSMD14 as a critical regulator of immune responses in breast cancer. Targeting PSMD14 enhances the effectiveness of immunotherapy by promoting PD-L1 degradation and remodeling the TME, offering a potential strategy to improve clinical outcomes.  \n†Shichao Wen andYuhan Liu contributed equally to this work.  \n*Correspondence:  \nJingxuan Wang [wangjingxuan@hrbmu.edu.cn](wangjingxuan@hrbmu.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/. The)[. The](http://creativecommons.org/licenses/by/4.0/. The)[ ](http://creativecommons.org/licenses/by/4.0/. The)Creative Commons Public Domain Dedication waiver ([http://creativecommons.org/publicdomain/zero/1.0/](htt","cbCaimHthiekzj2R","https://ap.wps.com/l/cbCaimHthiekzj2R","pdf",4361146,18,"English","# Abstract\n# Background\n# Methods\n# Results\n# Conclusion","[{\"question\":\"What problem does the study address in breast cancer immunotherapy?\",\"answer\":\"The study targets the challenge of achieving durable clinical responses to PD-1/PD-L1 inhibitors, which is hindered by an immunosuppressive tumor microenvironment (TME).\"},{\"question\":\"How does PSMD14 influence PD-L1 in breast cancer?\",\"answer\":\"PSMD14 stabilizes PD-L1 by interacting with its intracellular domain and removing K48-linked polyubiquitin chains, which inhibits proteasomal degradation.\"},{\"question\":\"What is the impact of inhibiting PSMD14 on the TME and immunotherapy response?\",\"answer\":\"Inhibition of PSMD14 enhances antigen presentation and CD8+ T cell activation, reduces regulatory T cells and MDSCs, alters macrophage polarization, and collectively improves immunotherapy effectiveness.\"}]","Targeting PSMD14 enhances immunotherapy efficacy by promoting PD-L1 degradation and reshaping the tumor microenvironment in breast cancer | PDF",1790109403,45,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6abc9750c72c05d48006ed894a0cc866.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cfd024bcda404674a6ad04d6172caca4.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b84705313f6d606e0193a224044a5318.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8c3d3a1b18224de8dae6eff66459dc72.webp",980,1306]